

## **Erratum: Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biologic disease-modifying antirheumatic drugs**

---

Charles-Schoeman C, Burmester G, Nash P, *et al.* Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biologic disease-modifying antirheumatic drugs. *Ann Rheum Dis* 2016;75:1293–1301. The second trial number has been corrected to NCT00550446

*Ann Rheum Dis* 2017;76:611. doi:10.1136/annrheumdis-2014-207178corr1

